Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T |
Journal | JOURNAL OF INFECTION AND CHEMOTHERAPY |
Volume | 26 |
Pagination | 625-632 |
Date Published | JUN |
Type of Article | Article |
ISSN | 1341-321X |
Mots-clés | Ciclesonide, Coronavirus disease 2019, Inhalation |
Résumé | No specific and effective anti-viral treatment has been approved for COVID-19 so far. Systemic corticosteroid has been sometimes administered to severe infectious diseases combined with the specific treatment. However, as lack of the specific anti-SARS-CoV-2 drug, systemic steroid treatment has not been recommended for COVID-19. We report here three cases of the COVID-19 pneumonia successfully treated with ciclesonide inhalation. Rationale of the treatment is to mitigate the local inflammation with inhaled steroid that stays in the lung and to inhibit proliferation of the virus by antiviral activity. Larger and further studies are warranted to confirm the result of these cases. (C) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. |
DOI | 10.1016/j.jiac.2020.04.007 |